ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,538,958 | +269.6% | 137,776 | +608.1% | 0.00% | +200.0% |
| Q2 2023 | $416,358 | +3.3% | 19,456 | +95.2% | 0.00% | 0.0% |
| Q1 2023 | $403,025 | -49.7% | 9,966 | -42.1% | 0.00% | -50.0% |
| Q4 2022 | $801,400 | +59.0% | 17,227 | +77.3% | 0.00% | +100.0% |
| Q3 2022 | $504,000 | +42.4% | 9,719 | +29.8% | 0.00% | 0.0% |
| Q2 2022 | $354,000 | -37.8% | 7,490 | -6.3% | 0.00% | 0.0% |
| Q1 2022 | $569,000 | -46.1% | 7,993 | -43.4% | 0.00% | -50.0% |
| Q4 2021 | $1,055,000 | +182.8% | 14,113 | +115.2% | 0.00% | +100.0% |
| Q3 2021 | $373,000 | +6.3% | 6,559 | -17.7% | 0.00% | 0.0% |
| Q2 2021 | $351,000 | -12.9% | 7,966 | -2.5% | 0.00% | 0.0% |
| Q1 2021 | $403,000 | -73.3% | 8,174 | -77.2% | 0.00% | -66.7% |
| Q4 2020 | $1,507,000 | -25.5% | 35,797 | -19.0% | 0.00% | 0.0% |
| Q3 2020 | $2,023,000 | -35.2% | 44,197 | -29.0% | 0.00% | -40.0% |
| Q2 2020 | $3,124,000 | -22.1% | 62,226 | -20.2% | 0.01% | -28.6% |
| Q1 2020 | $4,009,000 | -43.7% | 77,955 | -32.3% | 0.01% | -12.5% |
| Q4 2019 | $7,119,000 | -14.0% | 115,231 | -16.4% | 0.01% | -20.0% |
| Q3 2019 | $8,281,000 | -20.9% | 137,835 | +11.1% | 0.01% | -16.7% |
| Q2 2019 | $10,472,000 | -23.1% | 124,103 | -12.9% | 0.01% | -14.3% |
| Q1 2019 | $13,618,000 | +2.4% | 142,564 | -24.1% | 0.01% | -6.7% |
| Q4 2018 | $13,302,000 | +20.3% | 187,799 | +45.2% | 0.02% | +36.4% |
| Q3 2018 | $11,053,000 | -20.8% | 129,336 | +7.4% | 0.01% | -21.4% |
| Q2 2018 | $13,954,000 | +29.3% | 120,400 | -9.8% | 0.01% | +16.7% |
| Q1 2018 | $10,795,000 | +18.5% | 133,409 | -14.0% | 0.01% | +20.0% |
| Q4 2017 | $9,106,000 | +23.2% | 155,182 | -1.8% | 0.01% | +11.1% |
| Q3 2017 | $7,394,000 | +49.2% | 157,993 | +14.7% | 0.01% | +28.6% |
| Q2 2017 | $4,955,000 | +29.7% | 137,723 | +11.0% | 0.01% | +40.0% |
| Q1 2017 | $3,820,000 | +0.2% | 124,054 | +9.0% | 0.01% | 0.0% |
| Q4 2016 | $3,812,000 | +38.0% | 113,794 | +9.6% | 0.01% | +25.0% |
| Q3 2016 | $2,763,000 | +170.9% | 103,817 | +124.4% | 0.00% | +100.0% |
| Q2 2016 | $1,020,000 | -20.1% | 46,258 | +6.5% | 0.00% | 0.0% |
| Q1 2016 | $1,276,000 | -24.2% | 43,436 | -14.8% | 0.00% | -33.3% |
| Q4 2015 | $1,684,000 | -14.5% | 51,003 | -6.4% | 0.00% | -25.0% |
| Q3 2015 | $1,969,000 | -11.1% | 54,474 | +10.6% | 0.00% | 0.0% |
| Q2 2015 | $2,216,000 | +74.5% | 49,248 | +18.8% | 0.00% | +33.3% |
| Q1 2015 | $1,270,000 | -57.7% | 41,462 | -29.7% | 0.00% | -50.0% |
| Q4 2014 | $2,999,000 | +28.0% | 58,980 | -0.4% | 0.01% | 0.0% |
| Q3 2014 | $2,343,000 | +160.3% | 59,200 | +183.3% | 0.01% | +200.0% |
| Q2 2014 | $900,000 | – | 20,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |